0.95Open0.95Pre Close0 Volume2 Open Interest17.50Strike Price0.00Turnover76.02%IV5.16%PremiumDec 20, 2024Expiry Date0.05Intrinsic Value100Multiplier22DDays to Expiry0.90Extrinsic Value100Contract SizeAmericanOptions Type-0.4641Delta0.1225Gamma13.42Leverage Ratio-0.0288Theta-0.0051Rho-6.23Eff Leverage0.0170Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet